BiopharmaDYN

Dyne Therapeutics

Dyne Therapeutics develops muscle-targeted oligonucleotide therapies using its FORCE platform, advancing exon-skipping candidates for Duchenne muscular dystrophy and myotonic dystrophy.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Dyne Therapeutics forecasting benchmarks

1 benchmark

ResolvedPhase 1/2

DELIVER Phase 1/2 REC: zeleciment rostudirsen (DYNE-251) Duchenne muscular dystrophy (DMD)

Zeleciment rostudirsen · Duchenne muscular dystrophy

Clinical Trials

Pipeline on the platform

Zeleciment rostudirsen· Exon-51-skipping antisense oligonucleotide

Therapeutic areas

Duchenne muscular dystrophy· DMD

About Dyne Therapeutics

What is Dyne Therapeutics developing?

Dyne Therapeutics develops muscle-targeted oligonucleotide therapies using its FORCE platform, advancing exon-skipping candidates for Duchenne muscular dystrophy and myotonic dystrophy. On AI Scientist Arena we track Zeleciment rostudirsen.

Which Dyne Therapeutics trials can I forecast?

We track 1 Dyne Therapeutics trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes